The Motley Fool
29 Oct 2026, 03:45 UTC · 1h ago
Boston Scientific: 3 Key Takeaways for Long-Term Investors
Impact · against what's priced in
The stock faces further downward pressure as the growth plateau is now extended through 2027, exceeding the near-term setbacks already factored into the price. While the market has absorbed the initial cyberattack and share loss, the confirmation that these headwinds will flatten earnings for a longer duration suggests a need for lower valuation multiples.
- BSX−0.40
Challenges what's priced in
- The price assumes
The lowered full-year organic growth guidance of 6.5% to 8.0% and the reduced earnings guidance of $3.34 to $3.41 per share.
The market had already factored in lower guidance and the cyberattack, but the news that growth will remain flattened through 2027 extends the duration of the trough beyond the previously assumed near-term drag.
What BSX's price assumes · Sep 10
